Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 49

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 49
---
| United Therapeutics Corporation | ​ | ​ | UTHR   | ​ | ​ | ​ | ​ | 2,110.9 | ​                                                         | ​ | ​ | ​ | ​ | 11.0 | ​                                                        | ​ |
| Pacira                          | ​ | ​ | PCRX   | ​ | ​ | ​ | ​ |   669.2 | ​                                                         | ​ | ​ | ​ | ​ |  1.7 | ​                                                        | ​ |

+ Company added to peer group for 2024 For 2024, the People & Compensation Committee removed Emergent BioSolutions, Inc. due to their revenues and market capitalization now falling significantly outside the peer group criteria, and added ANI Pharmaceuticals, Inc. due to being aligned to most or all the peer criteria and being potential executive talent competitors. V. ELEMENTS OF OUR EXECUTIVE COMPENSATION PROGRAM The People & Compensation Committee reviews and considers the performance of each named executive officer and considers the amount of compensation: • we are willing to pay to retain each named executive officer; • we would have to pay to replace each named executive officer; and • that the named executive officer could otherwise command in the competitive employment market. The primary elements of our executive compensation program are: Base Salaries We use competitive base salaries to attract and retain qualified executives with the knowledge, skills, and abilities necessary to successfully execute their job responsibilities to help us achieve our growth and performance goals. Base salaries are intended to recognize a named executive officer’s immediate contribution to our organization, as well as his or her experience, knowledge, and responsibilities.

62 | investor.pacira.com

TABLE OF CONTENTS Executive Compensation

Our People & Compensation Committee annually evaluates adjustments to named executive officer base salary levels, including: • recommendations from our chief executive officer (for named executive officers other than himself); • the named executive officer’s skills and experience; • the particular importance of the named executive officer’s position to us; • the named executive officer’s individual performance; • the named executive officer’s growth in his or her position; and • the results of Aon’s comparative assessment regarding base salaries for comparable positions at peer companies. For newly hired executive officers, the People & Compensation Committee establishes initial base salaries through arm’s-length negotiations at the time the executive officer is hired, considering the position and the executive’s experience, qualifications, and the competitive market. After considering the above factors, in January 2024, our People & Compensation Committee approved merit increases to the 2024